

January 26, 2022

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Approval of Partial Amendments to Indications and Usage
of Ezetimibe Tablets 10mg “KMP” for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, received an approval of partial amendments to indications of Ezetimibe Tablets 10mg “KMP” on January 26, 2022 as below.

Outline of Ezetimibe Tablets 10mg “KMP”

Classes	Product Name	Original Brand Name
Cholesterol absorption inhibitor from small intestine Therapeutic agent for hyperlipemia	Ezetimibe Tablets 10mg “KMP”	Zetia Tablets 10mg

Outline of Amendments to Indications and Usage of Ezetimibe Tablets 10mg “KMP”

Indications and Usage	Hypercholesterolemia, Familial hypercholesterolemia, and <u>Homozygous sitosterolemia</u>
--------------------------	---

(Underlined parts are revised parts.)